Medtronic (NYSE:MDT) said it won CE Mark approval from the European Union for its Viva/Brava line of cardiac rhythm management devices. The medical device company said the Viva and Brava products, which are cardiac resynchronization therapy with defibrillation devices, feature a new algorithm it calls AdaptivCRT designed to optimize their CRT-D treatment. The software helped reduce right ventricular pacing by 44%, reducing unnecessary treatment and prolonging the life of the devices, according to a press release.
